{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:39:20Z","timestamp":1789522760679,"version":"build-2803163510"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA120439"],"award-info":[{"award-number":["R01CA120439"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Z01-BC006161"],"award-info":[{"award-number":["Z01-BC006161"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canine Health Foundation","award":["02321"],"award-info":[{"award-number":["02321"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-GM136629"],"award-info":[{"award-number":["T32-GM136629"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>High-grade meningioma is an aggressive type of brain cancer that is often recalcitrant to surgery and radiotherapy, leading to poor overall survival. Currently, there are no FDA-approved drugs for meningioma, highlighting the need for new therapeutic options, but development is challenging due to the lack of predictive preclinical models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To leverage the known overexpression of procaspase-3 in meningioma, PAC-1, a blood-brain barrier penetrant procaspase-3 activator, was evaluated for its ability to induce apoptosis in meningioma cells. To enhance the effects of PAC-1, combinations with either hydroxyurea or temozolomide were explored in cell culture. Both combinations were further investigated in small groups of canine meningioma patients and assessed by MRI, and the novel apoptosis tracer, [18F]C-SNAT4, was evaluated in patients treated with PAC-1 + HU.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In meningioma cell lines in culture, PAC-1 + HU are synergistic while PAC-1 + TMZ show additive-to-synergistic effects. In canine meningioma patients, PAC-1 + HU led to stabilization of disease and no change in apoptosis within the tumor, whereas PAC-1 + TMZ reduced tumor burden in all three canine patients treated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggest PAC-1 + TMZ as a potentially efficacious combination for the treatment of human meningioma, and also demonstrate the utility of including pet dogs with meningioma as a means to assess anticancer strategies for this common brain tumor.<\/jats:p><\/jats:sec>","DOI":"10.1093\/neuonc\/noab161","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T03:26:44Z","timestamp":1625196404000},"page":"1723-1735","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients"],"prefix":"10.1093","volume":"23","author":[{"given":"Emily J","family":"Tonogai","sequence":"first","affiliation":[{"name":"Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"},{"name":"Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C","family":"Botham","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"},{"name":"Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K","family":"Joslyn","sequence":"additional","affiliation":[{"name":"VetCT Australia, Fremantle, West Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory B","family":"Daniel","sequence":"additional","affiliation":[{"name":"Radiology, Department of Small Animal Clinical Sciences, Virgina-Maryland College of Veterinary Medicine, Blacksburg, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Chen","sequence":"additional","affiliation":[{"name":"Departments of Radiology and Chemistry, Stanford Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Rao","sequence":"additional","affiliation":[{"name":"Departments of Radiology and Chemistry, Stanford Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chemistry and Synthesis Center, NHLBI, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falguni","family":"Basuli","sequence":"additional","affiliation":[{"name":"Chemistry and Synthesis Center, NHLBI, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Rossmeisl","sequence":"additional","affiliation":[{"name":"Neurology and Neurosurgery, Department of Small Animal Clinical Sciences, Virgina-Maryland College of Veterinary Medicine, Blacksburg, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Riggins","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M","family":"Fan","sequence":"additional","affiliation":[{"name":"Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"},{"name":"Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"},{"name":"Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-3581","authenticated-orcid":false,"given":"Paul J","family":"Hergenrother","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"},{"name":"Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"},{"name":"Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"issue":"6","key":"2021100111121700900_CIT0001","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.3171\/2013.10.FOCUS13341","article-title":"Recent developments in chemotherapy for meningiomas: a review","volume":"35","author":"Moazzam","year":"2013","journal-title":"Neurosurg Focus."},{"issue":"S5","key":"2021100111121700900_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014","volume":"19","author":"Ostrom","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"2021100111121700900_CIT0003","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/biomedicines6030086","article-title":"Emerging medical treatments for meningioma in the molecular era","volume":"6","author":"Nigim","year":"2018","journal-title":"Biomedicines"},{"issue":"Suppl 1","key":"2021100111121700900_CIT0004","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/neuonc\/noy178","article-title":"Molecular and translational advances in meningiomas","volume":"21","author":"Suppiah","year":"2019","journal-title":"Neuro Oncol."},{"key":"2021100111121700900_CIT0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41525-017-0014-7","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"NPJ Genomic Med"},{"key":"2021100111121700900_CIT0006","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fonc.2019.00096","article-title":"Immunohistochemical characterization of procaspase-3 overexpression as a druggable target with PAC-1, a procaspase-3 activator, in canine and human brain cancers","volume":"9","author":"Schlein","year":"2019","journal-title":"Front Oncol."},{"issue":"11","key":"2021100111121700900_CIT0007","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1021\/acschembio.9b00338","article-title":"Procaspase-3 overexpression in cancer: a paradoxical observation with therapeutic potential","volume":"14","author":"Boudreau","year":"2019","journal-title":"ACS Chem Biol."},{"issue":"1","key":"2021100111121700900_CIT0008","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jmb.2009.03.003","article-title":"PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition","volume":"388","author":"Peterson","year":"2009","journal-title":"J Mol Biol."},{"issue":"11","key":"2021100111121700900_CIT0009","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1073\/pnas.111085198","article-title":"Maintenance of caspase-3 proenzyme dormancy by an intrinsic \u201csafety catch\u201d regulatory tripeptide","volume":"98","author":"Roy","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"46","key":"2021100111121700900_CIT0010","doi-asserted-by":"crossref","first-page":"80124","DOI":"10.18632\/oncotarget.19085","article-title":"Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients","volume":"8","author":"Joshi","year":"2017","journal-title":"Oncotarget."},{"issue":"1","key":"2021100111121700900_CIT0011","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00432-005-0048-6","article-title":"Expression of apoptosome pathway-related transcripts in non-small cell lung cancer","volume":"132","author":"Krepela","year":"2006","journal-title":"J Cancer Res Clin Oncol."},{"issue":"10","key":"2021100111121700900_CIT0012","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nchembio814","article-title":"Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy","volume":"2","author":"Putt","year":"2006","journal-title":"Nat Chem Biol."},{"issue":"8","key":"2021100111121700900_CIT0013","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.molonc.2014.06.015","article-title":"A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts","volume":"8","author":"Wang","year":"2014","journal-title":"Mol Oncol."},{"issue":"7","key":"2021100111121700900_CIT0014","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood-2014-01-546796","article-title":"Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells","volume":"125","author":"Patel","year":"2015","journal-title":"Blood."},{"issue":"43","key":"2021100111121700900_CIT0015","doi-asserted-by":"crossref","first-page":"E4079","DOI":"10.1073\/pnas.1315587110","article-title":"Intrinsic-mediated caspase activation is essential for cardiomyocyte hypertrophy","volume":"110","author":"Putinski","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2021100111121700900_CIT0016","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1021\/mp200673n","article-title":"Differential effects of procaspase-3 activating compounds in the induction of cancer cell death","volume":"9","author":"West","year":"2012","journal-title":"Mol Pharm."},{"issue":"8","key":"2021100111121700900_CIT0017","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1021\/acscentsci.6b00165","article-title":"Small-molecule procaspase-3 activation sensitizes cancer to treatment with diverse chemotherapeutics","volume":"2","author":"Botham","year":"2016","journal-title":"ACS Cent Sci."},{"issue":"2","key":"2021100111121700900_CIT0018","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jss.2014.11.004","article-title":"Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non-small cell lung cancer","volume":"194","author":"Razi","year":"2015","journal-title":"J Surg Res."},{"issue":"8","key":"2021100111121700900_CIT0019","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1535-7163.MCT-16-0025","article-title":"The combination of vemurafenib and procaspase-3 activation is synergistic in mutant BRAF melanomas","volume":"15","author":"Peh","year":"2016","journal-title":"Mol Cancer Ther."},{"key":"2021100111121700900_CIT0020","doi-asserted-by":"crossref","first-page":"TPS2605","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS2605","article-title":"Phase I study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies","volume":"34","author":"Danciu","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"2021100111121700900_CIT0021","doi-asserted-by":"crossref","first-page":"CT027","DOI":"10.1158\/1538-7445.AM2019-CT027","article-title":"Phase I study of procaspase activating compound -1 (PAC-1) in the treatment of advanced malignancies and in combination with temozolomide in refractory high-grade astrocytomas","volume":"79","author":"Danciu","year":"2019","journal-title":"Cancer Res"},{"issue":"18","key":"2021100111121700900_CIT0022","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics."},{"issue":"5","key":"2021100111121700900_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0178322","article-title":"Genomic profile of human meningioma cell lines","volume":"12","author":"Mei","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"2021100111121700900_CIT0024","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1593\/neo.08642","article-title":"The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP","volume":"10","author":"Striedinger","year":"2008","journal-title":"Neoplasia."},{"key":"2021100111121700900_CIT0025","doi-asserted-by":"crossref","first-page":"TPS2621","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS2621","article-title":"Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies","volume":"36","author":"Danciu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021100111121700900_CIT0026","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology."},{"issue":"2","key":"2021100111121700900_CIT0027","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec\u00ae plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J Neurooncol."},{"key":"2021100111121700900_CIT0028","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.wneu.2015.09.060","article-title":"Combined hydroxyurea and verapamil in the clinical treatment of refractory meningioma: human and orthotopic xenograft studies","volume":"86","author":"Karsy","year":"2016","journal-title":"World Neurosurg."},{"issue":"1","key":"2021100111121700900_CIT0029","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ajco.12419","article-title":"Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299","volume":"12","author":"Huang","year":"2016","journal-title":"Asia Pac J Clin Oncol."},{"issue":"11","key":"2021100111121700900_CIT0030","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin Drug Saf."},{"issue":"18","key":"2021100111121700900_CIT0031","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia","volume":"118","author":"Ware","year":"2011","journal-title":"Blood."},{"issue":"3","key":"2021100111121700900_CIT0032","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect."},{"issue":"5","key":"2021100111121700900_CIT0033","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"1","key":"2021100111121700900_CIT0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cancergencyto.2008.07.006","article-title":"Methylation status of MGMT gene promoter in meningiomas","volume":"187","author":"de Robles","year":"2008","journal-title":"Cancer Genet Cytogenet."},{"issue":"5","key":"2021100111121700900_CIT0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.21873\/cgp.20096","article-title":"Pyrosequencing analysis of MGMT promoter methylation in meningioma","volume":"15","author":"Panagopoulos","year":"2018","journal-title":"Cancer Genomics Proteomics."},{"issue":"3","key":"2021100111121700900_CIT0036","doi-asserted-by":"crossref","first-page":"67e","DOI":"10.1177\/030089161209800321","article-title":"Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review","volume":"98","author":"Scorsetti","year":"2012","journal-title":"Tumori."},{"issue":"1","key":"2021100111121700900_CIT0037","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11060-015-2016-6","article-title":"Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response","volume":"127","author":"Pellerino","year":"2016","journal-title":"J Neurooncol."},{"issue":"12","key":"2021100111121700900_CIT0038","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","article-title":"Improving human cancer therapy through the evaluation of pet dogs","volume":"20","author":"LeBlanc","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"324","key":"2021100111121700900_CIT0039","doi-asserted-by":"crossref","first-page":"324ps5","DOI":"10.1126\/scitranslmed.aaf0746","article-title":"Perspectives from man\u2019s best friend: National Academy of Medicine\u2019s Workshop on Comparative Oncology","volume":"8","author":"LeBlanc","year":"2016","journal-title":"Sci Transl Med."},{"issue":"1","key":"2021100111121700900_CIT0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/vco.12152","article-title":"Canine brain tumours: a model for the human disease?","volume":"15","author":"Hicks","year":"2017","journal-title":"Vet Comp Oncol."},{"issue":"5","key":"2021100111121700900_CIT0041","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1354\/vp.42-5-550","article-title":"Microarray analysis of differentially expressed genes of primary tumors in the canine central nervous system","volume":"42","author":"Thomson","year":"2005","journal-title":"Vet Pathol."},{"issue":"3","key":"2021100111121700900_CIT0042","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1939-1676.2008.00042.x","article-title":"Magnetic resonance imaging and histological classification of intracranial meningiomas in 112 dogs","volume":"22","author":"Sturges","year":"2008","journal-title":"J Vet Intern Med."},{"issue":"5","key":"2021100111121700900_CIT0043","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s10637-010-9445-z","article-title":"Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs","volume":"29","author":"Lucas","year":"2011","journal-title":"Invest New Drugs."},{"issue":"18","key":"2021100111121700900_CIT0044","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1158\/0008-5472.CAN-10-0766","article-title":"Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound","volume":"70","author":"Peterson","year":"2010","journal-title":"Cancer Res."},{"key":"2021100111121700900_CIT0045","article-title":"[18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies [published online ahead of print March 13, 2021]","author":"Chen","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"2021100111121700900_CIT0046","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-14-3176","article-title":"A systematic comparison of 18F-C-SNAT to established radiotracer imaging agents for the detection of tumor response to treatment","volume":"21","author":"Witney","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2021100111121700900_CIT0047","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2460\/javma.242.2.193","article-title":"Survival time following hospital discharge in dogs with palliatively treated primary brain tumors","volume":"242","author":"Rossmeisl","year":"2013","journal-title":"J Am Vet Med Assoc."},{"issue":"5","key":"2021100111121700900_CIT0048","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1227\/01.NEU.0000245597.46581.FB","article-title":"Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro","volume":"59","author":"Ragel","year":"2006","journal-title":"Neurosurgery."},{"issue":"3","key":"2021100111121700900_CIT0049","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021100111121700900_CIT0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-015-1812-3","article-title":"Combined treatment by octreotide and everolimus: octreotide enhances inhibitory effect of everolimus in aggressive meningiomas","volume":"124","author":"Graillon","year":"2015","journal-title":"J Neurooncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab161\/39625294\/noab161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/10\/1723\/40493860\/noab161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/10\/1723\/40493860\/noab161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T11:51:09Z","timestamp":1672660269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/10\/1723\/6314291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,7,3]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab161","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,7,3]]}}}